Li Bo, Yang Yaocheng, Dong Lina, Zhuang Dunmin, Pan Shixiang, Lu Haijun
Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, China.
Discov Oncol. 2025 Jul 7;16(1):1272. doi: 10.1007/s12672-025-03044-7.
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related death globally, with treatment challenges persisting in locally advanced or inoperable cases. To evaluate the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with chemoradiotherapy and immune drugs in patients with locally advanced non-small cell lung cancer (NSCLC) who could not undergo surgery.
A retrospective analysis was conducted on 190 patients with locally advanced NSCLC who could not undergo surgery. Patients were divided into group A (synchronous chemoradiotherapy combined with Endostar followed by immune consolidation therapy) and group B (synchronous chemoradiotherapy combined with Endostar followed by Endostar maintenance therapy). Treatment included continuous infusion of Endostar during radiotherapy, with a 21-day cycle. Radiotherapy was performed using intensity-modulated radiotherapy with conventional fractionation, delivering a dose of 60-66 Gy/30-33 fractions to the primary tumor and mediastinal lymph nodes over 6-7 weeks. Chemotherapy was platinum-based doublet chemotherapy. The recent efficacy, clinical benefit rate, disease progression time, overall survival time, and adverse reactions were observed.
The effective rates were 12% and 19.2%, and the disease control rates were 88% and 61.5% in groups A and B, respectively. The median progression-free survival (mPFS) was 29.83 months in group A and 8.73 months in group B, while the median overall survival (mOS) was 50.47 months in group A and 25.67 months in group B. The main adverse reactions in both groups were mostly grades 0-2.
Endostar combined with synchronous chemoradiotherapy followed by Endostar maintenance therapy can improve the survival of patients with locally advanced NSCLC who could not undergo surgery, without increasing adverse reactions, and has certain clinical guiding significance.
肺癌，尤其是非小细胞肺癌（NSCLC），仍然是全球癌症相关死亡的主要原因，在局部晚期或无法手术的病例中治疗挑战依然存在。旨在评估重组人血管内皮抑素（恩度）联合放化疗及免疫药物治疗无法手术的局部晚期非小细胞肺癌（NSCLC）患者的疗效及不良反应。
对190例无法手术的局部晚期NSCLC患者进行回顾性分析。患者分为A组（同步放化疗联合恩度序贯免疫巩固治疗）和B组（同步放化疗联合恩度序贯恩度维持治疗）。治疗包括放疗期间持续静脉滴注恩度，每21天为1个周期。放疗采用调强适形放疗，常规分割，在6 - 7周内给予原发肿瘤及纵隔淋巴结60 - 66 Gy/30 - 33次分割剂量。化疗采用含铂双药化疗。观察近期疗效、临床受益率、疾病进展时间、总生存时间及不良反应。
A组和B组的有效率分别为12%和19.2%，疾病控制率分别为88%和61.5%。A组的中位无进展生存期（mPFS）为29.83个月，B组为8.73个月；A组的中位总生存期（mOS）为50.47个月，B组为25.67个月。两组主要不良反应大多为0 - 2级。
恩度联合同步放化疗序贯恩度维持治疗可提高无法手术的局部晚期NSCLC患者的生存率，且不增加不良反应，具有一定的临床指导意义。
